FDA Moves to Restrict Mass Compounding of Obesity Drugs
The FDA proposed excluding weight-loss drugs from a key compounding list. The move limits bulk production and supports sales for Novo Nordisk and Eli Lilly.
Xurve View
Insights:
Xurve View
The United States FDA proposed excluding weight-loss drugs from a key compounding list on April 30, driving ELI LILLY & CO shares up nearly 10%. The move targets large-scale production of semaglutide and tirzepatide by outsourcing facilities that currently offer cheaper, unauthorized versions. Restricting these knockoffs protects the revenue of pharmaceutical leaders while pressuring telehealth providers that rely on bulk compounded supplies.
